MedPath

JAPANESE GYNECOLOGIC ONCOLOGY GROUP.

🇯🇵Japan
Ownership
-
Employees
-
Market Cap
-
Website

Clinical Trials

27

Active:0
Completed:18

Trial Phases

4 Phases

Phase 1:1
Phase 2:5
Phase 3:7
+1 more phases

Drug Approvals

0

Drug Approvals

No drug approvals found

This company may not have drug approvals in our database

Clinical Trials

Distribution across different clinical trial phases (27 trials with phase data)• Click on a phase to view related trials

Not Applicable
14 (51.9%)
Phase 3
7 (25.9%)
Phase 2
5 (18.5%)
Phase 1
1 (3.7%)

Phase III Trial of Stage I Ovarian Cancer After Surgery

Phase 3
Recruiting
Conditions
Epithelial Ovarian Cancer
Interventions
Drug: adjuvant chemotherapy
First Posted Date
2019-08-21
Last Posted Date
2019-08-30
Lead Sponsor
Japanese Gynecologic Oncology Group
Target Recruit Count
360
Registration Number
NCT04063527
Locations
🇯🇵

Aichi Medical University Hospital, Nagakute-shi, Aichi, Japan

🇯🇵

Tosei General Hospital, Seto-shi, Aichi, Japan

🇯🇵

Fujita Health University Hospital, Toyoake-shi, Aichi, Japan

and more 100 locations

Trial of Tri-weekly TJ Versus Weekly TJ for Stage II-IV Mullerian Carcinoma

Phase 3
Completed
Conditions
Primary Peritoneal Cancer
Epithelial Ovarian Cancer
Fallopian Tube Cancer
Interventions
Drug: Paclitaxel+Carboplatin
First Posted Date
2005-09-27
Last Posted Date
2020-02-17
Lead Sponsor
Japanese Gynecologic Oncology Group
Target Recruit Count
637
Registration Number
NCT00226915
Locations
🇯🇵

National Cancer Center Hospital, Chuo-ku, Tokyo, Japan

News

No news found

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.